Nucleotide-binding oligomerization domain 1/toll-like receptor 4 co-engagement promotes non-speci fi c immune response against k562 cancer cells

HIGHLIGHTS

• who: Domain and collaborators from the Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia University of Bonn, Germany have published the article: Nucleotide-Binding Oligomerization Domain 1/Toll-Like Receptor 4 Co-Engagement Promotes Non-Speci fi c Immune Response Against K562 Cancer Cells, in the Journal: (JOURNAL)
• what: We shed more light on the structural requirements of iE-DAP derivatives for NOD1 agonism.
• how: The data were analysed using the LEGENDplex Data Analysis Software Suite (BioLegend). HEK-Blue NOD1 cells were incubated for 20 h with C12-iE-DAP (1 µM) and . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.